In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pharmion licenses cancer candidate from MethylGene

Executive Summary

Pharmion (oncology and hematology therapeutics) has licensed from fellow cancer drug developer MethylGene research, development, and commercialization rights to histone deacetylase (HDAC) inhibitors, including MethylGene's Phase I MGCD0103 for solid tumors and blood cancers as well as the company's pipeline of second-generation HDAC inhibitors for cancer indications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Co-Promotion
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register